Literature DB >> 11527924

Association of HLA class I and class II antigen expression and mortality in uveal melanoma.

C Ericsson1, S Seregard, A Bartolazzi, E Levitskaya, S Ferrone, R Kiessling, O Larsson.   

Abstract

PURPOSE: Malignant transformation of cells is frequently associated with abnormalities in human leukocyte antigen (HLA) expression. These abnormalities may play a role in the clinical course of the disease, because HLA antigens mediate interactions of tumor cells with T cells and NK cells. Uveal melanoma is a highly malignant tumor of the eye and is characterized by a hematogenic spread to the liver. Little is known about the role of HLA expression in progression of this malignant disease.
METHODS: In the present study HLA class I antigen, beta(2)-microglobulin (beta(2)-m), and HLA class II antigen expression was analyzed in primary uveal melanoma lesions by immunoperoxidase staining with monoclonal antibodies of 65 archival clinical samples. The results were correlated with the clinical course of the disease.
RESULTS: HLA class I antigen expression and beta(2)-m expression were downregulated in 40 and 35 lesions, respectively. HLA class II antigens were expressed in 30 lesions. Patients with high HLA class I, including beta(2)-m, and HLA class II antigen expression in their primary melanoma lesions had a significantly decreased survival (P = 0.009, P < 0.001, and P = 0.006, respectively).
CONCLUSIONS: The findings argue against a major role of cytotoxic T-lymphocyte (CTL)-mediated control of tumor growth in the clinical course of uveal melanoma and are compatible with a potential role of NK-cell-mediated control of hematogenic metastatic spread.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11527924

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  29 in total

1.  Inflammatory cytokines in eyes with uveal melanoma and relation with macrophage infiltration.

Authors:  Long V Ly; Inge H G Bronkhorst; Els van Beelen; Johannes Vrolijk; Andrew W Taylor; Mieke Versluis; Gregorius P M Luyten; Martine J Jager
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-06-10       Impact factor: 4.799

Review 2.  Ocular diseases: immunological and molecular mechanisms.

Authors:  Jing Song; Yi-Fei Huang; Wen-Jing Zhang; Xiao-Fei Chen; Yu-Mian Guo
Journal:  Int J Ophthalmol       Date:  2016-05-18       Impact factor: 1.779

Review 3.  Immune escape mechanisms of intraocular tumors.

Authors:  Jerry Y Niederkorn
Journal:  Prog Retin Eye Res       Date:  2009-06-27       Impact factor: 21.198

Review 4.  Uveal melanoma as a target for immune-therapy.

Authors:  Marc Oliva; Antonio J Rullan; Josep M Piulats
Journal:  Ann Transl Med       Date:  2016-05

Review 5.  Macrophage physiology in the eye.

Authors:  Holly R Chinnery; Paul G McMenamin; Samantha J Dando
Journal:  Pflugers Arch       Date:  2017-02-23       Impact factor: 3.657

6.  Molecular profiling of primary uveal melanomas with tumor-infiltrating lymphocytes.

Authors:  Pierre L Triozzi; Lynn Schoenfield; Thomas Plesec; Yogen Saunthararajah; Raymond R Tubbs; Arun D Singh
Journal:  Oncoimmunology       Date:  2014-10-31       Impact factor: 8.110

7.  Characterization of signaling function and expression of HLA class I molecules in medulloblastoma.

Authors:  Courtney Smith; Mariarita Santi; Elisabeth J Rushing; Robert Cornelison; Tobey J MacDonald; Stanislav Vukmanovic
Journal:  J Neurooncol       Date:  2010-09-02       Impact factor: 4.130

Review 8.  Medulloblasoma: challenges for effective immunotherapy.

Authors:  Adam M Sonabend; Alfred T Ogden; Lisa M Maier; David E Anderson; Peter Canoll; Jeffrey N Bruce; Richard C E Anderson
Journal:  J Neurooncol       Date:  2011-12-16       Impact factor: 4.130

9.  A novel role of HLA class I in the pathology of medulloblastoma.

Authors:  Courtney Smith; Mariarita Santi; Bhargavi Rajan; Elisabeth J Rushing; Mi Rim Choi; Brian R Rood; Robert Cornelison; Tobey J MacDonald; Stanislav Vukmanovic
Journal:  J Transl Med       Date:  2009-07-12       Impact factor: 5.531

10.  Transporter associated protein expression in uveal melanoma.

Authors:  S Krishnakumar; S A Lakshmi; D Abhyankar; J Biswas
Journal:  Br J Ophthalmol       Date:  2004-07       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.